Transcutaneous supraorbital neurostimulation for the prevention of chronic migraine: a prospective, open-label preliminary trial

Abstract

Since chronic migraine is difficult to treat and often associated with medication overuse, non-invasive neurostimulation approaches are worth investigating. Transcutaneous supraorbital neurostimulation using the Cefaly® device is promising as a non-invasive preventive treatment for episodic migraine, but no data are available for chronic migraine. Our aim was to perform a preliminary evaluation of the efficacy of the Cefaly® device for the prophylaxis of chronic migraine with or without medication overuse. Primary endpoints were 50% reduction in monthly migraine days and 50% reduction in monthly medication use over 4 months. In an open-label study, twenty-three consecutive headache center patients with chronic migraine, diagnosed according to International Headache Society criteria, were recruited prospectively. After informed consent, patients were trained to use Cefaly® and instructed to use it for 20 min daily over 4 months. All patients received active neurostimulation. Thirty-five percent of the patients enrolled in the study achieved the study endpoints. Over half the patients had a greater than 50% reduction in acute medication consumption.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2

References

  1. 1.

    Natoli J, Manack A, Dean B et al (2010) Global prevalence of chronic migraine: a systematic review. Cephalalgia 30:599–609

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Evers S, Marziniak M (2010) Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol 9:391–401

    Article  PubMed  Google Scholar 

  3. 3.

    D’Amico D, Grazzi L, Usai S et al (2011) Disability in chronic daily headache: state of the art and future directions. Neurol Sci 32:S71–S76

    Article  PubMed  Google Scholar 

  4. 4.

    Manack AN, Buse DC, Lipton RB (2011) Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep 15:70–78

    Article  PubMed  Google Scholar 

  5. 5.

    Jürgens TP, Leone M (2013) Pearls and pitfalls: neurostimulation in headache. Cephalalgia 33:512–525

    Article  PubMed  Google Scholar 

  6. 6.

    Magis D, Schoenen J (2012) Advances and challenges in neurostimulation for headaches. Lancet Neurol 11:708–719

    Article  PubMed  Google Scholar 

  7. 7.

    Magis D, Jensen R, Schoenen J (2012) Neurostimulation therapies for primary headache disorders: present and future. Curr Opin Neurol 25:269–276

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Gallagher RM, Kunkel R (2003) Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache 43:36–43

    Article  PubMed  Google Scholar 

  9. 9.

    Schoenen J, Vandersmissen B, Jeangette S et al (2012) Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology 80:697–704

    Article  Google Scholar 

  10. 10.

    Headache Classification Committee of the International Headache Society (IHS) (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33(9):629-808. doi:10.1177/0333102413485658

    Article  Google Scholar 

  11. 11.

    D’Amico D, Leone M, Grazzi L et al (2008) When should “chronic migraine” patients be considered “refractory” to pharmacological prophylaxis? Neurol Sci 29:S55–S58

    Article  PubMed  Google Scholar 

  12. 12.

    Mathew NT (2009) Dynamic optimization of chronic migraine treatment: current and future options. Neurology 72:S14–S20

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Andrasik F, Grazzi L, Usai S et al (2007) Disability in chronic migraine with medication overuse: treatment effects at 3 years. Headache 47:1277–1281

    Article  PubMed  Google Scholar 

  14. 14.

    Zwart JA, Dyb G, Hagen K et al (2003) Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT study. Neurology 61:160–164

    Article  PubMed  Google Scholar 

  15. 15.

    Katsarava Z, Schneeweiss S, Kurth T et al (2004) Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 62:788–790

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Bigal ME, Lipton RB (2009) What predicts the change from episodic to chronic migraine? Curr Opin Neurol 22:269–276

    Article  PubMed  Google Scholar 

  17. 17.

    Katsarava Z, Muessig M, Dzagnidze A et al (2005) Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia 25:12–15

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Bigal ME, Serrano D, Buse D et al (2008) Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 48:1157–1168

    Article  PubMed  Google Scholar 

  19. 19.

    Bigal ME, Rapoport AM, Sheftell FD et al (2004) Transformed migraine and medication overuse in a tertiary headache centre-clinical characteristics and treatment outcomes. Cephalalgia 24:483–490

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Freitag FG, Lake A 3rd, Lipton R, US Headache Guidelines Consortium, Section on Inpatient Treatment Chairpersons et al (2004) Inpatient treatment of headache: an evidence-based assessment. Headache 44:342–360

    Article  PubMed  Google Scholar 

  21. 21.

    Zeeberg P, Olesen J, Jensen R (2006) Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia 26:1192–1198

    CAS  Article  PubMed  Google Scholar 

  22. 22.

    Saper JR, Lake AE 3rd, Cantrell DT et al (2002) Chronic daily headache prophylaxis with tizanidine: a doubleblind, placebo-controlled, multicenter outcome study. Headache 42:470–482

    Article  PubMed  Google Scholar 

  23. 23.

    Spira PJ, Beran RG, Australian Gabapentin Chronic Daily Headache Group (2003) Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology 61:1753–1759

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    Yurekli VA, Akhan G, Kutluhan S et al (2008) The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain 9:37–41

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  25. 25.

    Mei D, Ferraro D, Zelano G et al (2006) Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. Clin Neuropharmacol 29:269–275

    CAS  Article  PubMed  Google Scholar 

  26. 26.

    Silvestrini M, Bartolini M, Coccia M et al (2003) Topiramate in the treatment of chronic migraine. Cephalalgia 23:820–824

    CAS  Article  PubMed  Google Scholar 

  27. 27.

    Diener HC, Bussone G, Van Oene JC, TOPMAT-MIG-201(TOP-CHROME) Study Group et al (2007) Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 27:814–823

    Article  PubMed  Google Scholar 

  28. 28.

    Silberstein S, Lipton RB, Dodick DW et al (2007) Efficacy and safety of topiramate in the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 47:170–180

    Article  PubMed  Google Scholar 

  29. 29.

    Silberstein SD, Blumenfeld AM, Cady RK et al (2013) OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci 331:48–56

    CAS  Article  PubMed  Google Scholar 

  30. 30.

    Dodick DW, Turkel CC, DeGryse RE, PREEMPT Chronic Migraine Study Group et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50:921–936

    Article  PubMed  Google Scholar 

  31. 31.

    Aurora SK, Dodick DW, Turkel CC, PREEMPT 1 Chronic Migraine Study Group et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30:793–803

    CAS  Article  PubMed  Google Scholar 

  32. 32.

    Diener HC, Dodick DW, Aurora SK, PREEMPT 2 Chronic Migraine Study Group et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30:804–814

    CAS  Article  PubMed  Google Scholar 

  33. 33.

    Leone M, Franzini A, Bussone G (2001) Stereotactic stimulation of posterior hypothalamic gray matter in a patient with intractable cluster headache. N Engl J Med 345:1428–1429

    CAS  Article  PubMed  Google Scholar 

  34. 34.

    Lambru G, Matharu MS (2014) Peripheral neurostimulation in primary headaches. Neurol Sci 35:77–81

    Article  PubMed  Google Scholar 

  35. 35.

    Saper JR, Dodick DW, Silberstein SD et al (2011) Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia 31:271–285

    Article  PubMed  PubMed Central  Google Scholar 

  36. 36.

    Bartsch T, Paemeleire K, Goadsby PJ (2009) Neurostimulation approaches to primary headache disorders. Curr Opin Neurol 22:262–268

    Article  PubMed  Google Scholar 

  37. 37.

    Popeney CA, Alo´ KM (2003) Peripheral neurostimulation for the treatment of chronic, disabling transformed migraine. Headache 43:369–375

    Article  PubMed  Google Scholar 

  38. 38.

    Dodick DW, Silberstein SD, Reed KL et al (2015) Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: long-term results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia 35:344–358

    Article  PubMed  Google Scholar 

  39. 39.

    Tepper SJ, Rezai A, Narouze S et al (2009) Acute treatment of intractable migraine with sphenopalatine ganglion electrical stimulation. Headache 49:983–989

    Article  PubMed  Google Scholar 

  40. 40.

    Noseda R, Burstein R (2013) Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain 154:S44–S53

    CAS  Article  PubMed  Google Scholar 

  41. 41.

    Bartsch T, Goadsby PJ (2003) The trigeminocervical complex and migraine: current concepts and synthesis. Curr Pain Headache Rep 7:371–376

    CAS  Article  PubMed  Google Scholar 

  42. 42.

    Matharu MS, Bartsch T, Ward N et al (2004) Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain 127:220–230

    Article  PubMed  Google Scholar 

  43. 43.

    D’Amico D (2010) Pharmacological prophylaxis of chronic migraine: a review of double-blind placebo-controlled trials. Neurol Sci 31:S23–S28 (369–375)

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Paola Di Fiore.

Ethics declarations

Funding

This study had no external funding source. Cefaly® devices were made available by the manufacturer (Cefaly Technology, Liège, Belgium) free of charge, for use in the study, Cefaly® Technology had no role in the design or conduct of the study

Conflict of interest

The authors certify that there is no actual or potential conflict of interest in relation to this article.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Di Fiore, P., Bussone, G., Galli, A. et al. Transcutaneous supraorbital neurostimulation for the prevention of chronic migraine: a prospective, open-label preliminary trial. Neurol Sci 38, 201–206 (2017). https://doi.org/10.1007/s10072-017-2916-7

Download citation

Keywords

  • Chronic migraine
  • Migraine prophylaxis
  • Medication overuse
  • Transcutaneous supraorbital neurostimulation